The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Nextrast (Inst); Novocure (Inst); Nucana (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme; Nucana
 
Matthew Reilley
No Relationships to Disclose
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; BioMed Valley Discoveries; Seagen
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Christos Fountzilas
Research Funding - Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
 
Eduardo Castanon Alvarez
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Adnan Nagrial
No Relationships to Disclose
 
Nataliya Volodymyrivna Uboha
Stock and Other Ownership Interests - Exact Sciences (I); Natera (I)
Consulting or Advisory Role - Aptitude Health; Astellas Pharma; Astellas Pharma; AstraZeneca; BostonGene; Bristol Myers Squibb Foundation; Bristol-Myers Squibb/Roche; Eisai/MSD; Elevation Oncology; GRAIL; Helsinn Therapeutics; Ipsen; ipsen; Pfizer
Research Funding - EMD Serono (Inst); ipsen (Inst)
 
Sophia Frentzas
Honoraria - Amgen
Consulting or Advisory Role - Akeso Biopharma (Inst)
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Anne M. Noonan
Consulting or Advisory Role - AstraZeneca; AstraZeneca (I); Deciphera (I); Eisai; Exelixis; GOG Foundation (I); Helsinn Healthcare; Immunogen (I); Merck (I); OncLive/MJH Life Sciences; OncLive/MJH Life Sciences (I); QED Therapeutics
 
Wells A. Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Amgen; Criterium (Inst); QED Therapeutics; Zymeworks
Research Funding - ALX Oncology (Inst); Beigene (Inst); CanBas (Inst); D3 (Inst); Exelixis (Inst); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst)
 
Nick Pavlakis
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - Bayer (Inst); Pfizer (Inst); Roche (Inst)
 
Niharika B. Mettu
Research Funding - Amgen (Inst); Amphivena (Inst); Aravive (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); ERYTECH Pharma (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Mereo BioPharma (Inst); Repare Therapeutics (Inst); Syros Pharmaceuticals (Inst)
 
Paul Smith
Consulting or Advisory Role - AstraZeneca; Ono Pharmaceutical
 
Elina Murtomaki
Employment - AstraZeneca
 
Veronique Bragulat
Employment - AstraZeneca; GlaxoSmithKline
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline
 
Zachary A. Cooper
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Rakesh Kumar
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Evidera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly O. (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Pharmaceutical (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Endeavor Biomedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly O. (Inst); Loxo (Inst); Lyell Immunopharma (Inst); MacroGenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Peloton Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagan (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Synthekine (Inst); Taiho Oncology (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis